A detailed history of Buckingham Strategic Partners transactions in Astrazeneca PLC stock. As of the latest transaction made, Buckingham Strategic Partners holds 6,094 shares of AZN stock, worth $392,697. This represents 0.01% of its overall portfolio holdings.

Number of Shares
6,094
Previous 4,156 46.63%
Holding current value
$392,697
Previous $324,000 46.3%
% of portfolio
0.01%
Previous 0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$76.67 - $87.62 $148,586 - $169,807
1,938 Added 46.63%
6,094 $474,000
Q2 2024

Aug 13, 2024

SELL
$66.81 - $80.83 $175,777 - $212,663
-2,631 Reduced 38.77%
4,156 $324,000
Q1 2024

May 15, 2024

BUY
$61.03 - $69.57 $157,396 - $179,421
2,579 Added 61.29%
6,787 $459,000
Q4 2023

Feb 14, 2024

BUY
$61.89 - $69.28 $62,075 - $69,487
1,003 Added 31.29%
4,208 $283,000
Q3 2023

Nov 14, 2023

BUY
$64.85 - $71.7 $207,844 - $229,798
3,205 New
3,205 $217,000

Others Institutions Holding AZN

About ASTRAZENECA PLC


  • Ticker AZN
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 3,099,020,032
  • Market Cap $200B
  • Description
  • AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...
More about AZN
Track This Portfolio

Track Buckingham Strategic Partners Portfolio

Follow Buckingham Strategic Partners and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Buckingham Strategic Partners, based on Form 13F filings with the SEC.

News

Stay updated on Buckingham Strategic Partners with notifications on news.